YTEN - Yield10 Bioscience, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
6.19
-0.01 (-0.16%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close6.20
Open6.34
Bid6.08 x 800
Ask6.20 x 1100
Day's Range6.03 - 6.37
52 Week Range3.50 - 51.20
Volume45,549
Avg. Volume727,566
Market Cap12.196M
Beta (5Y Monthly)2.88
PE Ratio (TTM)N/A
EPS (TTM)-19.76
Earnings DateMay 14, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Yield10 Bioscience Begins 2020 Field Test Program to Evaluate Novel Yield Traits in Camelina and Canola

    Yield10 Bioscience, Inc. (YTEN), an agricultural bioscience company, today announced it has begun its 2020 Field Test Program based on the recent completion of planting at all sites contracted for the trials in the United States and Canada. Yield10’s 2020 Field Test Program is designed to evaluate several novel traits in Camelina and canola and the Company expects to harvest the plants and begin reporting data from the field tests in the fourth quarter of 2020. “We are pleased to report that our field trial contractors completed planting at all of the sites planned for our 2020 Field Test Program,” said Dr. Kristi Snell, Ph.D., Chief Science Officer of Yield10 Bioscience.

  • Yield10 Bioscience, Inc. (NASDAQ:YTEN) Just Reported, And Analysts Assigned A US$13.33 Price Target
    Simply Wall St.

    Yield10 Bioscience, Inc. (NASDAQ:YTEN) Just Reported, And Analysts Assigned A US$13.33 Price Target

    Yield10 Bioscience, Inc. (NASDAQ:YTEN) defied analyst predictions to release its first-quarter results, which were...

  • GlobeNewswire

    Yield10 Bioscience Announces First Quarter 2020 Financial Results

    WOBURN, Mass., May 14, 2020 -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today reported financial results for the three months ended March 31,.

  • GlobeNewswire

    Yield10 Bioscience Secures Regulatory Permits for U.S. and Canadian Sites and Announces Plans for 2020 Field Test Program in Camelina and Canola

    Yield10 Bioscience, Inc. (YTEN), an agricultural bioscience company, today announced that the Company has secured all of the regulatory permits required to conduct field tests for multiple traits at sites in the United States and Canada contracted for the 2020 growing season. Yield10’s 2020 Field Test Program will evaluate several novel traits in Camelina and canola. Yield10 utilizes the oilseed plant Camelina sativa to rapidly evaluate the activity of novel performance traits for development in Camelina as well as for licensing in key commercial crops, including canola, soybean, corn and other crops.

  • GlobeNewswire

    Yield10 Bioscience to Announce First Quarter 2020 Financial Results and Host a Conference Call on Thursday, May 14, 2020

    Yield10 Bioscience, Inc. (YTEN), an agricultural bioscience company, announced today that the Company will report its first quarter 2020 financial results and provide a corporate update on Thursday, May 14, 2020. Management will host a conference call on Thursday, May 14, 2020 at 6:00 p.m. ET to review financial results, share corporate highlights, and provide an overall business update. International callers should call +1-201-689-8354.

  • GlobeNewswire

    Yield10 Bioscience Announces Change of 2020 Annual Meeting of Stockholders to a Virtual Meeting

    Yield10 Bioscience, Inc. (YTEN), an agricultural bioscience company,  announced today a change in the format of its Annual Meeting of Shareholders ("Annual Meeting") from an in-person to a virtual-only meeting, via webcast, due to the emerging public health impact of the coronavirus pandemic (COVID-19) and to support the health and well-being of the Company's shareholders, employees and their families. At the time Yield 10 Bioscience filed its definitive proxy materials on March 25, 2020, it had disclosed the possibility of hosting a virtual annual meeting in lieu of its customary in-person annual meeting as part of its precautions regarding the coronavirus or COVID-19. The annual meeting will be accessible to stockholders via the link: http://viewproxy.com/yield10bio/2020/vm.

  • GlobeNewswire

    Yield10 Bioscience Obtains Positive Response from USDA-APHIS on Regulatory Status of its CRISPR Genome-Edited C3007 Trait in Camelina, Paving the Way for U.S. Field Tests

    Yield10 Bioscience, Inc. (YTEN), an agricultural bioscience company, today announced that it has obtained a positive response from USDA-APHIS’s Biotechnology Regulatory Services (BRS) for its CRISPR genome-edited C3007 trait in Camelina sativa plant lines designed to increase oil content. Yield10’s submission along with the USDA-APHIS BRS response is posted on the USDA’s website. In January 2020, Yield10 submitted an “Am I Regulated?” letter to the BRS, requesting confirmation of the regulatory status for Camelina plant lines containing the Company’s novel, CRISPR genome-edited C3007 trait.

  • We're A Little Worried About Yield10 Bioscience's (NASDAQ:YTEN) Cash Burn Rate
    Simply Wall St.

    We're A Little Worried About Yield10 Bioscience's (NASDAQ:YTEN) Cash Burn Rate

    Just because a business does not make any money, does not mean that the stock will go down. For example, although...

  • GlobeNewswire

    Yield10 Bioscience Announces Fourth Quarter and Full Year 2019 Financial Results

    WOBURN, Mass., March 19, 2020 -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today reported financial results for the three and twelve months.

  • GlobeNewswire

    Yield10 Bioscience Announces Results of 2019 Field Test Program

    Yield10 Bioscience, Inc. (YTEN), an agricultural bioscience company, today announced the results from field tests conducted in the 2019 growing season in the United States and Canada. Data from the field tests suggest that novel traits can be successfully deployed in the oil biosynthesis pathway using CRISPR genome-editing technology to boost seed oil content in Camelina. Additional results recorded in the field studies suggest that the activity and expression of trait C3004 can boost photosynthetic efficiency in Camelina, an outcome that supports further field work in 2020.

  • ACCESSWIRE

    Yield10 Bioscience, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 19, 2020 / Yield10 Bioscience, Inc. (NASDAQ:YTEN) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 19, 2020 at ...

  • GlobeNewswire

    Yield10 Bioscience to Announce Fourth Quarter and Full Year 2019 Financial Results and Host a Conference Call on Thursday, March 19, 2020

    WOBURN, Mass., March 12, 2020 -- Yield10 Bioscience, Inc. (NASDAQ: YTEN), an agricultural bioscience company, announced today that the Company will report its fourth quarter.

  • GlobeNewswire

    Yield10 Bioscience Achieves Key Milestones in Early Development Program in Corn to Evaluate Novel Traits

    Yield10 Bioscience, Inc. (YTEN), an agricultural bioscience company, announced today that it achieved key milestones in an early development program in corn to evaluate novel seed yield traits. Corn is the highest value commercial crop grown in the United States. The Company’s corn program began in early 2019, centered around the successful deployment of novel traits discovered by Yield10 into corn by a major third-party agriculture company partner.

  • GlobeNewswire

    Yield10 Bioscience Appoints Agriculture Industry Veteran Sherri M. Brown, Ph.D., to Board of Directors

    Yield10 Bioscience, Inc. (Nasdaq:YTEN today announced that Sherri M. Brown, Ph.D. was appointed to the Company’s Board of Directors effective February 11, 2020. In connection with her appointment, Dr. Brown will serve as chair of a newly formed Science and Technology Committee of the Board. Dr. Brown previously served as a Special Commercial and Technical Advisor to the Company.

  • GlobeNewswire

    Yield10 Bioscience Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

    Yield10 Bioscience, Inc. (YTEN), an agricultural bioscience company that uses its “Trait Factory” to develop high value seed traits for the agriculture and food industries, announced today that it has received a letter from The Nasdaq Stock Market LLC notifying the Company that it has regained compliance with the Nasdaq Capital Market’s minimum bid price continued listing requirement. The letter noted that as of January 30, 2020, the Company evidenced a closing bid price of its common stock in excess of the $1.00 minimum requirement for at least ten consecutive trading days. Accordingly, the Company has regained compliance with Nasdaq Marketplace Rule 5550(a)(2) and Nasdaq considers the matter closed.

  • Have Insiders Been Buying Yield10 Bioscience, Inc. (NASDAQ:YTEN) Shares?
    Simply Wall St.

    Have Insiders Been Buying Yield10 Bioscience, Inc. (NASDAQ:YTEN) Shares?

    We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...

  • GlobeNewswire

    Yield10 Bioscience Submits "Am I Regulated?" Letter to USDA-APHIS BRS for CRISPR Genome-Edited C3007 in Camelina to Pave the Way for U.S. Field Tests

    Yield10 Bioscience, Inc. (YTEN), an agricultural bioscience company that uses its “Trait Factory” to develop high value seed traits for the agriculture and food industries, today announced that it has submitted an "Am I Regulated?" letter to USDA-APHIS's Biotechnology Regulatory Services (BRS) to confirm that the use of CRISPR genome-edited trait C3007 in Camelina sativa plant lines for increased oil content does not meet the definition of a regulated article under 7 CFR Part 340 regulations. Once regulatory status of the plants is confirmed, Yield10 plans to conduct field tests of CRISPR genome-edited Camelina plants in the United States. “We have applied considerable effort and resources into the discovery and early development of a portfolio of novel traits with the potential to increase oil content in oilseed crops,” said Dr. Kristi Snell, Ph.D., Chief Science Officer of Yield10 Bioscience.

  • GlobeNewswire

    Yield10 Bioscience Announces 1-for-40 Reverse Stock Split

    Yield10 Bioscience, Inc. (YTEN), an agricultural bioscience company that uses its “Trait Factory” to develop high value seed traits for the agriculture and food industries, today announced that it will effect a 1-for-40 reverse stock split of its common stock, following stockholder approval of the reverse stock split at the Company's special stockholders meeting held on January 9, 2020. The 1-for-40 reverse stock split will be effective as of the close of business on Wednesday, January 15, 2020 and the Company's common stock will begin trading on a split-adjusted basis on Thursday, January 16, 2020. The reverse stock split will reduce the number of shares of the Company’s common stock currently outstanding from 39,986,201 shares to 999,655 shares.

  • Yield10 shareholders approve reverse stock split
    American City Business Journals

    Yield10 shareholders approve reverse stock split

    Woburn-based agricultural company Yield10 Bioscience Inc. received shareholder approval to undergo a reverse stock split in order to avoid being delisted by the Nasdaq, the company revealed in a public filing Thursday.

  • Agri-biotech Yield10 plans reverse stock split to avoid Nasdaq delisting
    American City Business Journals

    Agri-biotech Yield10 plans reverse stock split to avoid Nasdaq delisting

    Woburn-based agricultural company Yield10 Bioscience Inc. is seeking stakeholders approval to effect a reverse stock split to address the risk of being delisted by the Nasdaq, the company revealed in a recent public filing.

  • Hedge Funds Watching Yield10 Bioscience, Inc. (YTEN) From Afar
    Insider Monkey

    Hedge Funds Watching Yield10 Bioscience, Inc. (YTEN) From Afar

    Hedge funds are known to underperform the bull markets but that's not because they are terrible at stock picking. Hedge funds underperform because their net exposure in only 40-70% and they charge exorbitant fees. No one knows what the future holds and how market participants will react to the bountiful news that floods in each […]

  • GlobeNewswire

    Yield10 Bioscience Announces Closing of $11.5 Million Equity Offering and Full Exercise of Over-allotment Option

    Yield10 Bioscience, Inc. (YTEN) an agricultural bioscience company which uses its “Trait Factory” to develop high value seed traits for the agriculture and food industries, announced today the closing of an equity offering, which consisted of an underwritten public offering of units and a private placement of units for gross proceeds of $11.5 million, which includes the full exercise of the underwriter's over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses payable by Yield10 Bioscience. Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE MKT:LTS), is sole book-running manager and placement agent in connection with the public offering and the private placement.

  • GlobeNewswire

    Yield10 Bioscience Announces Pricing of $10.75 Million Equity Offering

    Yield10 Bioscience, Inc. (YTEN) an agricultural bioscience company which uses its “Trait Factory” to develop high value seed traits for the agriculture and food industries, announced today the pricing of a $10,750,000 equity offering, which consisted of an underwritten public offering of units and a private placement of units for gross proceeds of $10.75 million, prior to deducting underwriting discounts and commissions and offering expenses payable by Yield10 Bioscience. In a concurrent private placement, investors affiliated with Jack W. Schuler have agreed to purchase 5,750 unregistered units, priced at $1,000 per unit, with each unit consisting of one share of Series B preferred stock, having a conversion price of $0.20, seven and one-half year warrants to purchase 5,000 shares of common stock with an exercise price of $0.20 per share, and two and one-half year warrants to purchase 5,000 shares of common stock with an exercise price of $0.20 per share.

  • GlobeNewswire

    Yield10 Bioscience Announces Third Quarter 2019 Financial Results

    WOBURN, Mass., Nov. 12, 2019 -- Yield10 Bioscience, Inc. (NASDAQ:YTEN), an agricultural bioscience company that uses its “Trait Factory” to develop high value seed traits for.

  • GlobeNewswire

    Yield10 Bioscience Chief Science Officer Dr. Kristi Snell to Present at the 7th Plant Genomics & Gene Editing Congress

    Yield10 Bioscience, Inc. (YTEN), an agricultural bioscience company that uses its “Trait Factory” to develop high value seed traits for the agriculture and food industries, today announced that Kristi Snell, Ph.D., Yield10’s Chief Science Officer, will present today at the 7th Plant Genomics & Gene Editing Congress. At the 7th Plant Genomics & Gene Editing Congress, Dr. Snell will present a talk titled “Crop Trait Development: Target selection and validation using the GRAIN Platform.” In the presentation, Dr. Snell will discuss strategies the Yield10 team has employed to identify and edit novel gene targets using CRISPR genome editing to improve seed yield and oil content in oilseed crops.